ARUP Laboratories Ink Partnership to Offer deCODE ProstateCancer™ Test
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
deCODE genetics and ARUP Laboratories have announced a partnership through which ARUP will offer deCODE’s DNA-based prostate cancer risk assessment test to its clients nationwide.
Under the terms of the non-exclusive agreement, ARUP will integrate deCODE ProstateCancer™ into the portfolio of tests it offers to leading academic medical centers, public and private healthcare providers, and major hospitals across the United States. ARUP’s clients will order the test, submit samples and receive results through ARUP, with deCODE conducting the genetic analysis in its CAP and CLIA-certified laboratory.
deCODE ProstateCancer measures 25 common single-letter variations, or SNPs, in the sequence of the human genome that are associated with the risk of prostate cancer. These SNPs were validated in tens of thousands of patients and controls in many populations.
“The management of patients with elevated or borderline PSA continues to be a challenge, and having the additional knowledge of a patient’s genetic risk for prostate cancer can be very useful. We are pleased to be working with deCODE, who has developed this test through a number of large clinical studies and continues to demonstrate excellent scientific productivity in the area of human genetics,” said Edward Ashwood, MD, President and CEO of ARUP Laboratories.
ARUP Laboratories plans to begin offering deCODE’s prostate cancer risk test (ARUP test code 2003326) to clients in the fall of 2010.
Under the terms of the non-exclusive agreement, ARUP will integrate deCODE ProstateCancer™ into the portfolio of tests it offers to leading academic medical centers, public and private healthcare providers, and major hospitals across the United States. ARUP’s clients will order the test, submit samples and receive results through ARUP, with deCODE conducting the genetic analysis in its CAP and CLIA-certified laboratory.
deCODE ProstateCancer measures 25 common single-letter variations, or SNPs, in the sequence of the human genome that are associated with the risk of prostate cancer. These SNPs were validated in tens of thousands of patients and controls in many populations.
“The management of patients with elevated or borderline PSA continues to be a challenge, and having the additional knowledge of a patient’s genetic risk for prostate cancer can be very useful. We are pleased to be working with deCODE, who has developed this test through a number of large clinical studies and continues to demonstrate excellent scientific productivity in the area of human genetics,” said Edward Ashwood, MD, President and CEO of ARUP Laboratories.
ARUP Laboratories plans to begin offering deCODE’s prostate cancer risk test (ARUP test code 2003326) to clients in the fall of 2010.
